Patients have been innovating for decades. HIV activists forced FDA action. The cystic fibrosis community moved Kalydeco from bench to bedside. People with breast cancer organized for access to Herceptin. Type 1 diabetes advocates normalized continuous glucose monitoring. Long COVID groups mapped symptoms and pushed for repurposed therapies. Different diseases, same playbook: build community‑run networks, get smart on the science, rewire trials and policy, and then use targeted leverage to change the rules — fast.
